financetom
Business
financetom
/
Business
/
Canada's Agnico Eagle Mines Q2 adjusted EPS beats expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canada's Agnico Eagle Mines Q2 adjusted EPS beats expectations
Jul 30, 2025 2:34 PM

Overview

* Agnico Eagle Q2 adjusted EPS beats analyst expectations, driven by strong gold production

* Record free cash flow achieved, more than doubling prior quarter, enhancing balance sheet

* Company transitions to net cash position, repaying $550 mln in long-term debt

Outlook

* Agnico Eagle maintains 2025 gold production guidance at 3.3-3.5 mln ounces

* Company reiterates 2025 total cash costs per ounce at $915-$965

* Agnico Eagle expects 2025 AISC per ounce at $1,250-$1,300

Result Drivers

* COST MANAGEMENT - Disciplined cost management helped achieve total cash costs below guidance mid-point despite higher royalty costs

* OPERATIONAL EXECUTION - Consistent operational execution led to strong production performance at Canadian Malartic, LaRonde, Macassa, and Fosterville

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $1.94 $1.68 (6

Adjusted Analysts

EPS )

Q2 $976 mln

Adjusted

Net

Income

Q2 Net $1.07

Income bln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the gold peer group is "buy"

* Wall Street's median 12-month price target for Agnico Eagle Mines Ltd ( AEM ) is C$196.00, about 11.3% above its July 29 closing price of C$173.83

* The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved